Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.
http://www.priceseries.com/trade/MYOV-Myovant-Sciences-Ltd-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2017081720170830.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments